855-115-0330 Services: Prescribing - Formulary or Protocol (1) A Pharmacist located and licensed in Oregon may prescribe and dispense an FDA-approved drug and device included on either the Formulary or pursuant to a statewide drug therapy protocol (Protocol), set forth in this Division. (2) A Pharmacist may submit a concept, on a form prescribed by the board to the Public Health and Pharmacy Formulary Advisory Committee for consideration, for the addition of a drug or device to the Formulary or for the development of a Protocol. A Pharmacist may provide feedback on the Formulary or Protocols on a board prescribed form and located on the board website. (3) A Pharmacist must only prescribe a drug or device consistent with the parameters of the Formulary or Protocol, and in accordance with federal and state regulations. (4) The Pharmacist is responsible for recognizing limits of knowledge and experience and for resolving situations beyond their expertise by consulting with or referring patients to another health care provider. (5) For each drug or device the Pharmacist prescribes via Protocol, the Pharmacist must: (a) Ensure training and education requirements have been met prior to engaging in prescribing activities. A copy of all required training and education must be retained according to OAR 855-104-0055; (b) Collect subjective and objective information about the patient’s health history and clinical status. If prescribing pursuant to the Formulary in OAR 855-115-0340, a diagnosis from the patient’s healthcare provider is required. (c) Assess the information collected in (b). Any physical assessment must be performed in a face-to-face, in-person interaction and not through electronic means. (d) Create an individualized patient-centered care plan that utilizes information obtained in the assessment to evaluate and develop a care plan; (e) Implement the care plan, to include: (A) Addressing medication and health-related problems and engaging in preventive care strategies; (B) Initiating, modifying, discontinuing, or administering medication therapy as permitted by the Formulary or Protocol; (C) Providing education and self-management training to the patient or caregiver; (D) Contributing to coordination of care, including the referral or transition of the patient to another health care professional; and (E) Scheduling follow-up care as needed to achieve goals of therapy;and (f) Monitor and evaluate the effectiveness of the care plan and make modifications to the plan. (6) For each drug or device the Pharmacist prescribes via Formulary, the Pharmacist must: (a) Ensure training and education requirements have been met prior to engaging in prescribing activities. A copy of all required training and education must be retained according to OAR 855-104-0055; and (b) Ensure prescribing is pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. (7) Provide notification to the patient’s identified primary care provider or other care providers when applicable within five business days following the prescribing of a Formulary or Protocol Compendia drug or device. (8) All records and documents must be retained according to OAR 855-104-0055 and must be made available to the patient and provider upon request. (9) Pharmacists must report the prescription and administration of vaccines to a patient’s primary health care provider if identified and to the Oregon Health Authority pursuant to ORS 689.645(4). The reporting of the prescription and administration of vaccines to a patient’s primary health care provider and to the Oregon Health Authority can be accomplished by reporting to the ALERT Immunization Information System (ALERT-IIS) per ORS 433.090, ORS 433.092, ORS 433.094, ORS 433.095, ORS 433.096, ORS 433.098, ORS 433.100, ORS 433.102, ORS 433.103, and ORS 433.104. Statutory/Other Authority: ORS 689.205 Statutes/Other Implemented: ORS 689.645 & ORS 689.649 History: BP 6-2025, amend filed 08/08/2025, effective 08/08/2025 BP 16-2023, adopt filed 08/16/2023, effective 03/01/2024